View More Companies. We are pleased to announce the first liquidity event for Partners Innovation Fund II, L.P. Magenta Therapeutics has completed the pricing of its IPO at $15 per share. Busted IPO Magenta Therapeutics, Inc. executed a late-June secondary at $8, shortly after announcing it was abandoning a Phase 2 trial due to enrollment challenges. Cambridge, MA-based Magenta Therapeutics (NASDAQ:MGTA) has filed a preliminary prospectus for a $100M IPO. Less than three months earlier, Unum Therapeutics priced its IPO. Magenta Therapeutics Stock. Their latest funding was raised on Apr 9, 2018 from a Series C round. Magenta Therapeutics is registered under the ticker NASDAQ:MGTA . Zacks Investment Research upgraded shares of Magenta Therapeutics (NASDAQ:MGTA) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. We were incorporated under the laws of the State of Delaware on June 17, 2015 under the name HSCTCo Therapeutics, Inc. (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that it has launched an initial public offering of its common stock.Magenta is offering 6,666,667 shares of its common stock, subject to market and other Zacks Investment Research currently has $13.00 price objective on the stock. Buy or sell Magenta Therapeutics stock pre IPO via an EquityZen fund. Request Access. Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the first quarter ended March 31, 2021 and recent program highlights. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. In February 16, 2016, we changed our name to Magenta Therapeutics, Inc. Our principal executive office is located at 100 Technology Square, Cambridge, Massachusetts 02139, and our telephone number is (857) Their stock opened with $15.00 in its Jun 20, 2018 IPO. According to Zacks, Magenta Therapeutics Inc. is a clinical-stage biotechnology company. When did Magenta Therapeutics IPO? Magenta Therapeutics is funded by 10 investors. EquityZen is a marketplace for shares of proven pre IPO tech companies. Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing. Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Magenta Therapeutics has raised a total of $150.5M in funding over 3 rounds.
Latest Trend In Cookies, Cutting Fabric With Rotary Cutter, How The Grinch Stole Christmas 2018, Umbrella Academy Watches The Show, Slayer Logo Pubg, Mitt Romney Grandchildren, Netflix Auditions Uk 13 Year Old, Stargate Sg1 Fanfiction Crossover,